Patients treated with SGLT2 inhibitors were more likely to be classified as CKD stage 2, whereas patients in the insulin group had a higher proportion of individuals in CKD stage 3a or 3b (Figure 2). This evidence concerns the gene SLC5A2 and chronic kidney disease.